OncoBeta GmbH

OncoBeta®GmbH is a private medical device company specializing in the development and commercialization of the latest innovative therapies utilizing epidermal radioisotope applications. Since its establishment, OncoBeta®GmbH has been committed to the development, regulatory approval, and commercialization of Rhenium-SCT® (Skin Cancer Therapy), an epidermal radioisotope therapy for non-melanoma skin cancer. Since then, OncoBeta® has successfully refined a customized application and device management system that complies with all health, safety, and environmental protection regulatory standards. OncoBeta®GmbH has obtained European CE certification and has applied for regulatory approval in several other countries outside the EU. Additionally, with a patient-focused approach, OncoBeta® is enthusiastically collaborating with medical, scientific, and industrial partners as well as local and national authorities to make this personalized, painless, and non-invasive treatment method available to patients worldwide. Rhenium-SCT® significantly improves the prognosis and quality of life for patients with non-melanoma skin cancer. OncoBeta GmbH is a pioneer in the field of radioisotopes, currently offering innovative skin cancer therapies for non-melanoma skin cancer and producing tungsten (Wolfram)-188 / R-188 (W / Re-188) generators for commercial use.